Biotech firm Immunic, Inc. announced significant progress in developing treatments for multiple sclerosis, with upcoming trial results and strengthened leadership bolstering their efforts. The company’s lead drug, vidofludimus calcium, shows promise in both relapsing and progressive forms of the disease.